Treatment of Nausea and Vomiting in Terminally Ill Cancer Patients

被引:35
作者
Glare, Paul A. [1 ]
Dunwoodie, David [2 ]
Clark, Katherine [3 ]
Ward, Alicia [4 ]
Yates, Patsy [5 ]
Ryan, Sharon [6 ]
Hardy, Janet R. [7 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Pain & Palliat Care Serv, New York, NY 10021 USA
[2] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia
[3] Univ Notre Dame, Darlinghurst, NSW, Australia
[4] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia
[5] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[6] Westmead Childrens Hosp, Westmead, NSW, Australia
[7] Mater Hosp, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
D O I
10.2165/0003495-200868180-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology and knowing the pharmacology of the drugs available for its amelioration. The following six main syndromes are identified: gastric stasis, biochemical, raised intracranial pressure, vestibular, mechanical bowel obstruction and ileus. A careful history, focused physical examination and appropriate investigations are needed to elucidate the syndrome and its cause, so that therapy is rational. Drugs are the mainstay of treatment in terminal cancer, and the main classes of antiemetic agents are prokinetics, dopamine antagonists, antihistamines, anticholinergics and serotonin antagonists. Dexamethasone and octreotide are also used, especially in bowel obstruction. Non-drug measures are important in relieving the associated distress. Patients should be able to die comfortably, without tubes. Despite decades of practice affirming this approach, the evidence base is weak and well designed studies are urgently needed.
引用
收藏
页码:2575 / 2590
页数:16
相关论文
共 138 条
[61]  
HEYKANTS J, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P61
[62]  
HEYKANTS J, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P27
[63]  
Hickok Jane T, 2007, Support Cancer Ther, V4, P247, DOI 10.3816/SCT.2007.n.022
[64]   PHARMACOKINETICS AND DOSE PROPORTIONALITY OF DOMPERIDONE IN HEALTHY-VOLUNTEERS [J].
HUANG, YC ;
COLAIZZI, JL ;
BIERMAN, RH ;
WOESTENBORGHS, R ;
HEYKANTS, JJP .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08) :628-632
[65]   MUSCARINIC RECEPTOR SUBTYPES [J].
HULME, EC ;
BIRDSALL, NJM ;
BUCKLEY, NJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1990, 30 :633-673
[66]   Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [J].
Hunt, TL ;
Gallagher, SC ;
Cullen, MT ;
Shah, AK .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (05) :589-596
[67]  
ISAH AO, 1991, BRIT J CLIN PHARMACO, V32, P677
[68]  
Jackson W Clay, 2003, J Palliat Med, V6, P251, DOI 10.1089/109662103764978506
[69]  
Jatoi A, 2004, J SUPPORT ONCOL, V2, P334
[70]  
Jatoi Aminah, 2004, J Support Oncol, V2, P323